| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BTS GUIDELINES |
treatment
Correspondence to:
Correspondence to:
Professor L P Ormerod
Professor of Respiratory Medicine, Blackburn Royal Infirmary, Blackburn, Lancashire BB2 3LR, UK; pandpormerod{at}hotmail.com
Guidelines have been compiled by The Joint Tuberculosis Committee of the British Thoracic Society to quantify the risks of reactivation of tuberculosis with anti-tumour necrosis factor 
(anti-TNF-) treatment. These guidelines are intended to inform respiratory physicians, gastroenterologists, rheumatologists and dermatologists, together with specialist nurses in those disciplines.
Keywords: tuberculosis; chemoprophylaxis; anti-TNF treatment; BTS guidelines
This article has been cited by other articles:
|
|
 |
|
  J. D. Pradeep, G. P. R. Clunie, K. Gaffney, N. J. Innes, A. Brooksby, P. Bradley, and A. Gulati Screening for Mycobacterium tuberculosis prior to anti-TNF therapy--an audit of impact of the British Thoracic Society guidelines on rheumatology practice in an area of low Mycobacterium tuberculosis prevalence Rheumatology, November 25, 2008; (2008) ken425v1. [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. Larsen, I. J. Sorensen, V. O. Thomsen, and P. Ravn Re-activation of bovine tuberculosis in a patient treated with infliximab Eur. Respir. J., July 1, 2008; 32(1): 229 - 231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sexton and A. C. Harrison Susceptibility to nontuberculous mycobacterial lung disease Eur. Respir. J., June 1, 2008; 31(6): 1322 - 1333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L P Ormerod and D S Rampton Authors' response Gut, March 1, 2008; 57(3): 425 - 426. [Full Text] [PDF]
|
|
|
|
|
|
V. V. Kaushik, S. Ambalavanan, and K. Binymin Comment on: Use of the QuantiFERON TB Gold test as part of a screening programme in patients with RA under consideration for treatment with anti-TNF-{alpha} agents: the Newcastle (UK) experience Rheumatology, December 1, 2007; 46(12): 1863 - 1864. [Full Text] [PDF]
|
|
|
|
|
|
A. Pratt, K. Nicholl, and L. Kay Comment on: Use of the QuantiFERON-TB(R) Gold test as part of a screening programme in patients with RA under consideration for treatment with anti-TNF-{alpha} agents: the Newcastle (UK) experience: reply Rheumatology, December 1, 2007; 46(12): 1864 - 1865. [Full Text] [PDF]
|
|
|
|
|
|
M. F. Botteman, J. W. Hay, M. P. Luo, A. S. Curry, R. L. Wong, and B. A. van Hout Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom Rheumatology, August 1, 2007; 46(8): 1320 - 1328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Pratt, K. Nicholl, and L. Kay Use of the QuantiFERON TB Gold test as part of a screening programme in patients with RA under consideration for treatment with anti-TNF-{alpha} agents: the Newcastle (UK) experience Rheumatology, June 1, 2007; 46(6): 1035 - 1036. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Milburn Key issues in the diagnosis and management of tuberculosis J R Soc Med, March 1, 2007; 100(3): 134 - 141. [Full Text] [PDF]
|
|
|
|
 |
|
 F. H. Krouwels Correspondence Anti-Tumor Necrosis Factor-{alpha} in Asthma Am. J. Respir. Crit. Care Med., February 1, 2007; 175(3): 288 - 288. [Full Text] [PDF]
|
|
|
|
|
|
E. M. Erin, O. M. Kon, P. J. Barnes, and T. T. Hansel Am. J. Respir. Crit. Care Med., February 1, 2007; 175(3): 288a - 289. [Full Text] [PDF]
|
|
|
|
 |
|
 J A Wedzicha, S L Johnston, and D M Mitchell Thorax update for the 60th year (October 2005-September 2006) Thorax, December 1, 2006; 61(12): 1035 - 1036. [Full Text] [PDF]
|
|
|
|
|
|
L. J. Kay, I. D. Griffiths, and for the BSR Biologics Register Management committe UK consultant rheumatologists' access to biological agents and views on the BSR Biologics Register Rheumatology, November 1, 2006; 45(11): 1376 - 1379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K L Winthrop Serious infections with antirheumatic therapy: are biologicals worse? Ann Rheum Dis, November 1, 2006; 65(suppl_3): iii54 - iii57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S J Bourke Interstitial lung disease: progress and problems. Postgrad. Med. J., August 1, 2006; 82(970): 494 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Oliveri, R Polosa, S T Holgate, P H Haworth, K S Babu, and H S Arshad Etanercept in chronic severe asthma * Authors' reply. Thorax, July 1, 2006; 61(7): 640 - 640. [Full Text] [PDF]
|
|
|
|
|
|
D J Dhasmana, J Nash, J C Bradley, D Creer, and G Provenzano TB screening and anti-TNF{alpha} treatment * Author's reply. Thorax, July 1, 2006; 61(7): 641 - 641. [Full Text] [PDF]
|
|
|
|
|
|
S Nizam and P Emery Attenuated response to purified protein derivative in patients with rheumatoid arthritis. Ann Rheum Dis, July 1, 2006; 65(7): 980 - 980. [Full Text] [PDF]
|
|
|
|
|
|
J. Ledingham, C. Wilkinson, and C. Deighton British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-{alpha} treatments Rheumatology, October 1, 2005; 44(10): 1205 - 1206. [Full Text] [PDF]
|
|
Read all eLetters
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
